Sutro Biopharma (STRO) Projected to Post Earnings on Monday

Sutro Biopharma (NASDAQ:STRO) is anticipated to issue its quarterly earnings data before the market opens on Monday, March 24th. Analysts expect the company to announce earnings of ($0.86) per share and revenue of $12.18 million for the quarter.

Sutro Biopharma (NASDAQ:STRO) last issued its quarterly earnings data on Thursday, March 13th. The company reported ($2.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by ($2.10). Sutro Biopharma had a negative return on equity of 101.89% and a negative net margin of 77.01%. The business had revenue of $14.00 million during the quarter, compared to the consensus estimate of $10.44 million. During the same period last year, the company earned ($1.78) earnings per share. On average, analysts expect Sutro Biopharma to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Sutro Biopharma Price Performance

Shares of STRO stock opened at $0.77 on Friday. The business has a 50 day simple moving average of $1.64 and a 200 day simple moving average of $2.62. The firm has a market capitalization of $63.24 million, a price-to-earnings ratio of -0.48 and a beta of 1.22. Sutro Biopharma has a 12-month low of $0.76 and a 12-month high of $6.13.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on STRO shares. Piper Sandler set a $2.00 price target on Sutro Biopharma in a research note on Friday, March 14th. Citizens Jmp downgraded shares of Sutro Biopharma from an “outperform” rating to a “market perform” rating in a research note on Friday, March 14th. Bank of America downgraded shares of Sutro Biopharma from a “buy” rating to an “underperform” rating and lowered their target price for the stock from $11.00 to $1.00 in a research report on Friday, March 14th. JMP Securities reaffirmed a “market outperform” rating and issued a $17.00 price target on shares of Sutro Biopharma in a research report on Wednesday, December 11th. Finally, Wells Fargo & Company reduced their target price on shares of Sutro Biopharma from $5.00 to $4.00 and set an “equal weight” rating for the company in a research note on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $6.63.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.